Expesicor Inc

Kalispell, MT · Biotech · Private

Animal models of drug-resistant epilepsy based on the KaL method for antiseizure drug screening

expesicor.com →
Grants
$1.1M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Modeling drug-refractory epilepsy with the KaL method™$343,042
Federal grantDepartment of Health and Human Services · Phase I · Modeling drug-refractory epilepsy with the KaL method$343,042
Federal grantDepartment of Health and Human Services · Phase I · Developing EXP-1801 as an imaging agent to quantify pain and analgesia$407,654
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2458ImmusanT, Inc.—$33M
2459GALECTIN THERAPEUTICS INC—$6.8M
2460Eidos Therapeutics—$26M
2461Expesicor Inc——
2462Actym Therapeutics, Inc.—$25M
2463Verseon Corp—$25M
2464Pharmazz, Inc.—$25M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.